NVST
Envista Holdings Corp
NVST has the edge over OSCR overall, supported by stronger valuation and stronger modeled upside.
OSCR
Oscar Health, Inc.
OSCR offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
NVST Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Stable | |
| Strong |
NVST's profitability and balance sheet are currently strong, and its revenue and cash flow are stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
NVST PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 6.4x | $24.66 | — |
| Forward | 15x | $24.66 | — |
| Cheap | 21x | $81.70 | +231% |
| Fair | 28x | $108 | +339% |
| Expensive | 95x | $368 | +1394% |
Historical ranges are pointers, not guarantees.
NVST has the edge over OSCR in the historical PE scenario, which offers more potential upside but is not a forecast.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
NVST Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for NVST, with profitability improving.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over NVST on the outlook, with more favorable valuation expectations.
NVST Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.62 | -58% |
| Q3 2026 | $3.87 | +4738% |
| Q2 2026 | $0.58 | +87% |
| Q1 2026 | $0.41 | +$6.95 |
| Q4 2025 | $0.28 | +$6.78 |
| Q3 2025 | $0.08 | +$7.84 |
| Q2 2025 | $0.31 | +$8.00 |
| Q1 2025 | -$6.54 | -$5.83 |
| Q4 2024 | -$6.50 | -$5.90 |
NVST has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
NVST Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $691.5M | +3.2% |
| Q2 2026 | $730.5M | +7.1% |
| Q1 2026 | $705.5M | +14% |
| Q4 2025 | $750.6M | +15% |
| Q3 2025 | $669.9M | +11% |
| Q2 2025 | $682.1M | +7.7% |
| Q1 2025 | $616.9M | -1.1% |
| Q4 2024 | $652.9M | +1.1% |
NVST's revenue has grown year over year for six quarters in a row: $692M last quarter, up 3.2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 75% | +66 points |
| Q2 2026 | 11% | +4.2 points |
| Q1 2026 | 8.9% | +2.5 points |
| Q4 2025 | 9.8% | +2.7 points |
| Q3 2025 | 8.6% | +5.1 points |
| Q2 2025 | 6.8% | +189 points |
| Q1 2025 | 6.3% | -1.4 points |
| Q4 2024 | 7.1% | +39 points |
NVST has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over NVST on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
NVST Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $61.8M | -9% |
| Q2 2026 | $104.3M | +37% |
| Q1 2026 | -$15.8M | -$10.2M |
| Q4 2025 | $91.7M | -26% |
| Q3 2025 | $67.9M | +7.3% |
| Q2 2025 | $76.4M | -11% |
| Q1 2025 | -$5.6M | -119% |
| Q4 2024 | $123.8M | +32% |
NVST still generates free cash flow, though less than at its 2020 peak: $242M over the past year.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over NVST on cash flow, with more consistent year-over-year improvement.
NVST Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -700K shares |
| 1 year | -1.6% | -2.7M shares |
| 3 years | -6.7% | -11.8M shares |
| 5 years | -8.3% | -14.7M shares |
| Available history | +20% | +27M shares |
NVST has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $10M |
| Q2 2026 | $60.3M |
| Q1 2026 | $42.7M |
| Q4 2025 | $24.3M |
| Q3 2025 | $42M |
| Q2 2025 | $85.7M |
| Q1 2025 | $14.6M |
NVST spent $137M buying back its own shares over the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
NVST Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.3x | Very low |
| Q2 2026 | 0.8x | Very low |
| Q1 2026 | 1.0x | Healthy |
| Q4 2025 | 0.7x | Very low |
| Q3 2025 | 1.1x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2024 | 12.5x | High |
| Q4 2023 | 8.5x | High |
NVST's net debt is less than a year of its operating earnings (EBITDA), down from 1.1 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over NVST on leverage, with a lower net debt burden relative to earnings.
NVST Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.8 | Neutral |
| Stochastic | 33.0 | Neutral |
NVST's weekly RSI is 49 (neutral) and its Stochastic is 33 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
NVST PE vs Healthcare Sector
| Metric | NVST | Sector median | Relative |
|---|---|---|---|
| PE | 6.4x | 26x | 75% below |
| PE % | 0 | 29 | 29 pts below |
NVST has the edge over OSCR on valuation relative to its sector.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
NVST Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $23.8 | 3.7% above |
| 20 week MA | $25.5 | 3.4% below |
| 50 week MA | $25.2 | 2.2% below |
| 100 week MA | $22.3 | 11% above |
| 200 week MA | $24.1 | 2.3% above |
NVST's trend is mixed: it's above three of its five weekly moving averages, and 2.3% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over NVST on trend strength, trading above more of its moving averages.
NVST Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $30.0 | $32.4 | +8.1% |
| 2021 | $32.4 | $45.7 | +41% |
| 2022 | $45.7 | $33.1 | -28% |
| 2023 | $33.1 | $24.1 | -27% |
| 2024 | $24.1 | $19.2 | -20% |
| 2025 | $19.2 | $22.0 | +14% |
| 2026 YTD | $22.0 | $24.7 | +12% |
NVST has finished lower in three of the last six years. It's up 12% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over NVST on returns for 2026, with the stronger performance.